Biotechnology firm ADC pulls listing amid latest IPO market jitters
Biotechnology company ADC Therapeutics SA postponed its planned $200 million (162.34 million pounds) U.S. initial public offering on Wednesday, citing adverse market conditions as it became the third company to pull a planned IPO in recent days.